NRx Pharmaceuticals’ (NRXP) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report published on Friday,Benzinga reports. The firm currently has a $19.00 price target on the stock.

Several other analysts have also recently issued reports on NRXP. Ascendiant Capital Markets increased their price objective on NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. D. Boral Capital reiterated a “buy” rating and issued a $31.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, January 28th.

NRx Pharmaceuticals Stock Up 13.5 %

NASDAQ:NRXP opened at $2.35 on Friday. The stock’s fifty day moving average is $3.02 and its two-hundred day moving average is $2.02. NRx Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $6.01. The stock has a market capitalization of $39.75 million, a price-to-earnings ratio of -1.10 and a beta of 1.22.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings data on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10). On average, sell-side analysts expect that NRx Pharmaceuticals will post -1.75 EPS for the current fiscal year.

Insider Activity at NRx Pharmaceuticals

In other NRx Pharmaceuticals news, Chairman Jonathan C. Javitt bought 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The shares were purchased at an average price of $1.17 per share, with a total value of $46,800.00. Following the completion of the acquisition, the chairman now directly owns 84,634 shares of the company’s stock, valued at $99,021.78. This represents a 89.62 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 19.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On NRx Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Townsquare Capital LLC purchased a new position in shares of NRx Pharmaceuticals during the third quarter worth about $25,000. Anson Funds Management LP purchased a new position in shares of NRx Pharmaceuticals during the third quarter worth about $241,000. Sassicaia Capital Advisers LLC purchased a new position in shares of NRx Pharmaceuticals during the fourth quarter worth about $33,000. AdvisorShares Investments LLC grew its holdings in shares of NRx Pharmaceuticals by 138.5% during the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock worth $683,000 after purchasing an additional 180,229 shares during the last quarter. Finally, Millennium Management LLC purchased a new position in shares of NRx Pharmaceuticals during the fourth quarter worth about $61,000. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.